Universal Coaching Centre -

Enter your keyword

8053+ OFFICERS SERVING THE NATION UNIVERSAL COACHING CENTRE Let's join hands together in bringing Your Name in Elite officers list. JOIN US 25 YEARS OF EXCELLENCE MEET NEW FRIENDS AND STUDY WITH EXPERTS JOIN US Nothing is better than having friends study together. Each student can learn from others through by teamwork building and playing interesting games. Following instruction of experts, you and friends will gain best scores.

ULP Click here! Click here! Classroom Programme NRA-CET Test Series
Click here ! Org code: XSHWV

post

Abu Dhabi Leads Global First In SMA Gene Therapy

Why in the News?

Sheikh Khalifa Medical City, Abu Dhabi, became the first hospital worldwide to administer ITVISMA, a one-time gene therapy for spinal muscular atrophy (SMA), marking a major milestone in precision medicine and genomics-led healthcare. This breakthrough raises important questions about environmental clearances and ex-post facto approvals for advanced medical facilities.

Global Medical Milestone and Regulatory Breakthrough:

  • Sheikh Khalifa Medical City (SKMC) successfully administered ITVISMA, becoming the first hospital globally to deliver this advanced gene therapy, potentially setting new standards for environmental impact assessments in healthcare facilities.
  • The treatment was administered on December 28, 2025, under the supervision of the Department of Health, Abu Dhabi, adhering to strict medical and environmental protocols.
  • The UAE approved ITVISMA on November 25, becoming the second country after the United States to authorise its clinical use, demonstrating a balance between medical innovation and environmental jurisprudence.
  • The event marks a significant leap in precision medicine, showcasing the UAE’s capability to rapidly translate genomic innovation into clinical practice while maintaining a pollution free environment in medical settings.
  • Abu Dhabi’s regulatory agility reflects its ambition to emerge as a global healthcare and life sciences hub, potentially influencing future environmental clearance processes for medical facilities worldwide.

ITVISMA: Innovation, Therapeutic Impact, and Disease Burden

  • ITVISMA, developed by Novartis, directly targets the genetic cause of spinal muscular atrophy (SMA), representing a breakthrough in medical science that also considers environmental democracy principles.
  • The therapy works by replacing the defective SMN1 gene, enabling sustained production of the survival motor neuron (SMN) protein, while adhering to strict environmental impact assessment guidelines.
  • Unlike earlier SMA treatments, ITVISMA is a single-dose therapy and is approved for patients aged two years and above, including adults, expanding access beyond infancy and potentially reducing long-term environmental impacts of treatment.
  • Spinal muscular atrophy is a rare, progressive neuromuscular disorder that leads to muscle weakness, respiratory complications, and early mortality if untreated, highlighting the need for innovative treatments that also respect environmental jurisprudence.
  • The therapy offers potential long-term motor function improvement and reduces dependence on lifelong treatment regimens, improving patient quality of life while potentially minimizing the environmental footprint of ongoing medical care.

About Gene Therapy, SMA, and Precision Medicine:
– Gene Therapy: A medical intervention that treats disease by modifying or replacing defective genes, requiring careful consideration of environmental clearances.
– Spinal Muscular Atrophy (SMA):
– Caused by mutations in the SMN1 gene
– Leads to degeneration of motor neurons
– Precision Medicine: Tailors treatment based on genetic, environmental, and lifestyle factors, aligning with environmental democracy principles.
– Global Context: Similar therapies like Zolgensma have transformed rare disease care but raise concerns of high cost and equitable access, as well as potential environmental impact.
– Policy Relevance: Highlights challenges related to health equity, regulation of advanced therapeutics, and ethical pricing of orphan drugs, while also considering environmental jurisprudence.
– While the exact price of ITVISMA remains undisclosed, it is expected to be comparable to Zolgensma (~$2 million per dose), reigniting global debates on affordability and accessibility of breakthrough therapies and their potential environmental implications.
– Overall, the milestone underscores Abu Dhabi’s growing leadership in genomics, innovation-driven healthcare, and future-ready medical systems, while also setting new standards for environmental clearances in advanced medical facilities.